IL13 and Alzheimer disease: Current systemic treatments approved for AD include the interleukin (IL) 4/IL13 inhibitor dupilumab; the IL13 inhibitor tralokinumab, and the JAK inhibitors abrocitinib, upadacitinib, and baricitinib.